Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Pahle, Jessica ^a   Menzel, Lutz ^b   Niesler, Nicole ^b   Kobelt, Dennis ^b   Aumann, Jutta ^a   Rivera, Maria ^c   Walther, Wolfgang ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Experimental Pharmacology and Oncology Berlin Buch GmbH   (Germany)

Author keywords

Clostridium perfringens enterotoxin (CPE); Colon cancer; Gene therapy; Suicide gene

Indexed keywords

BACTERIAL TOXIN; CLAUDIN 3; CLAUDIN 4; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; UNCLASSIFIED DRUG; CLDN3 PROTEIN, HUMAN; CLDN4 PROTEIN, HUMAN; ENTEROTOXIN; ENTEROTOXIN, CLOSTRIDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL DEATH; CLOSTRIDIUM PERFRINGENS; COLON CARCINOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SUICIDE GENE THERAPY; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BYSTANDER EFFECT; COLONIC NEOPLASMS; DRUG SCREENING; FEMALE; GENE THERAPY; GENETICS; NUDE MOUSE; PATHOLOGY; SUICIDE TRANSGENE;

ANIMALS; BYSTANDER EFFECT; CLAUDIN-3; CLAUDIN-4; CLOSTRIDIUM PERFRINGENS; COLONIC NEOPLASMS; ENTEROTOXINS; FEMALE; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012977896     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3123-x     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics: 2011. CA Cancer J Clin. 2011;61:69-90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
3. Touil Y, Igoudjil W, Corvaisier M, Dessein A-F, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot F-R, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res. 2014;20:837-46.
4. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen C-T, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-6. doi: 10.1038/nature11156.
5. Walther W, Stein U. Therapeutic genes for cancer gene therapy. Mol Biotechnol. 1999;13:21-8.
6. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev. 2009;61:572-88.
7. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005;65:9603-6.
8. Michl P, Gress TM. Bacteria and bacterial toxins as therapeutic agents for solid tumors. Curr Cancer Drug Targets. 2004;4:689-702.
9. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A. 2001;98:15155-60.
10. Zheng J, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther. 2003;10:764-70.
11. Walther W, Petkov S, Kuvardina ON, Aumann J, Kobelt D, Fichtner I, Lemm M, Piontek J, Blasig IE, Stein U, Schlag PM. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther. 2012;19:494-503.
12. Yang WS, Park S-O, Yoon A-R, Yoo JY, Kim MK, Yun C-O, Kim C-W. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol Cancer Ther. 2006;5:1610-9.
13. Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann K-H, Menke A, Fensterer H, Giehl K, Löhr M, Leder G, Iwamura T, Adler G, Gress TM. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003;63:6265-71. PMID:14559813.
14. Minton NP. Clostridia in cancer therapy. Nat Rev Microbiol. 2003;1:237-42.
15. Gao Z, McClane B a. Use of clostridium perfringens enterotoxin and the enterotoxin receptor-binding domain (C-CPE) for cancer treatment: opportunities and challenges. J Toxicol. 2012;2012:981626.
16. Johnson EA. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol. 1999;53:551-75.
17. Smedley JG, McClane BA. Fine Mapping of the N-Terminal Cytotoxicity Region of Clostridium perfringens Enterotoxin by Site-Directed Mutagenesis. Infect Immun. 2004;72:6914-23.
18. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem. 1997;272:26652-8.
19. Gumbiner B. Structure, biochemistry, and assembly of epithelial tight junctions. Am J Physiol. 1987;253:C749-58. PMID:3322036.
20. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol. 1995;269:G467-75. PMID:7485497.
21. Tsukita S, Furuse M. Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J Cell Biol. 2000;149:13-6.
22. Niessen CM. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol. 2007;127:2525-32.
23. Ding L, Lu Z, Lu Q, Chen Y-H. The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res. 2013;5:367-75. doi: 10.2147/CMAR.S38294.
24. Singh U, Van Itallie CM, Mitic LL, Anderson JM, McClane BA. CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large complex species, one of which contains the tight junction protein occludin. J Biol Chem. 2000;275:18407-17.
25. Chakrabarti G, Zhou X, McClane BA. Death pathways activated in CaCo-2 cells by Clostridium perfringens enterotoxin. Infect Immun. 2003;71:4260-70.
26. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186.
27. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology. 2005;46:551-60.
28. Lu Z, Ding L, Lu Q, Chen Y-H. Claudins in intestines: Distribution and functional significance in health and diseases. Tissue Barriers. 2013;1:24978.
29. Mees ST, Mennigen R, Spieker T, Rijcken E, Senninger N, Haier J, Bruewer M. Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin. Int J Colorectal Dis. 2009;24:361-8.
30. Kominsky SL, Tyler B, Sosnowski J, Brady K, Doucet M, Nell D, Smedley JG, McClane B, Brem H, Sukumar S. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res. 2007;67:7977-82.
31. Tabariès S, Siegel PM. The role of claudins in cancer metastasis. Oncogene. 2016. doi: 10.1038/onc.2016.289.
32. Rangel LBA, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003;9:2567-75.
33. Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, Fendrich V, Ring J, Sipos B, Tuveson DA, Bremer C, Gress TM, Michl P. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut. 2013;62:1034-43.
34. Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer. 2007;109:1312-22. doi: 10.1002/cncr.22536.
35. Neesse A, Griesmann H, Gress TM, Michl P. Claudin-4 as therapeutic target in cancer. Arch Biochem Biophys. 2012;524:64-70.
36. Saeki R, Kondoh M, Kakutani H, Tsunoda S, Mochizuki Y, Hamakubo T, Tsutsumi Y, Horiguchi Y, Yagi K. A Novel Tumor-Targeted Therapy Using a Claudin-4-Targeting Molecule. Mol Pharmacol. 2009;76:918-26.
37. Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther. 2009;8:1906-15. doi: 10.1158/1535-7163.MCT-09-0106.
38. Martín V, Cortés ML, de Felipe P, Farsetti A, Calcaterra NB, Izquierdo M. Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. Cancer Res. 2000;60:3218-24.
39. Lee EJ, Jameson JL. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum Gene Ther. 2002;13:533-42. doi: 10.1089/10430340252809829.
40. Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 2002;62:2576-82. PMID: 11980652.
41. Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AKM, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Curr Gene Ther. 2005;5:155-80.
42. Bhakdi S, Bayley H, Valeva A, Walev I, Walker B, Weller U, Kehoe M, Palmer M. Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Arch Microbiol. 1996;165:73-9.
43. Smedley JG, Uzal F a, McClane B a. Identification of a prepore large-complex stage in the mechanism of action of Clostridium perfringens enterotoxin. Infect Immun. 2007;75:2381-90. doi: 10.1128/IAI.01737-06.
44. Kokai-Kun JF, Benton K, Wieckowski EU, McClane BA. Identification of a Clostridium perfringens Enterotoxin Region Required for Large Complex Formation and Cytotoxicity by Random Mutagenesis. Infect Immun. 1999;67:5634-41.
45. Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, Sukumar S. Clostridium perfringens Enterotoxin Elicits Rapid and Specific Cytolysis of Breast Carcinoma Cells Mediated through Tight Junction Proteins Claudin 3 and 4. Am J Pathol. 2004;164:1627-33.
46. Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM. Claudin-4: A New Target for Pancreatic Cancer Treatment Using Clostridium perfringens Enterotoxin. Gastroenterology. 2001;121:678-84.
47. Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, Tsukita S. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. J Cell Biol. 1999;147:195-204. PMCID: PMC2164970.
48. Long H, Crean CD, Lee W, Cummings OW, Gabig TG. Expression of Clostridium Perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Prostate Cancer Epithelium. Cancer Res. 2001;1:7878-81.
49. Chakrabarti G, McClane BA. The importance of calcium influx, calpain and calmodulin for the activation of CaCo-2 cell death pathways by Clostridium perfringens enterotoxin. Cell Microbiol. 2005;7:129-46.
50. McClane BA. The complex interactions between Clostridium perfringens enterotoxin and epithelial tight junctions. Toxicon Off J Int Soc Toxinol. 2001;39:1781-91.
51. Shrestha A, Uzal FA, McClane BA. The interaction of Clostridium perfringens enterotoxin with receptor claudins. Anaerobe. 2016;41:18-26.
52. Veshnyakova A, Piontek J, Protze J, Waziri N, Heise I, Krause G. Mechanism of Clostridium perfringens enterotoxin interaction with claudin-3/-4 protein suggests structural modifications of the toxin to target specific claudins. J Biol Chem. 2012;287:1698-708.
53. Frieben WR, Duncan CL. Homology between enterotoxin protein and spore structural protein in Clostridium perfringens type A. Eur J Biochem. 1973;39:393-401. PMID: 4359628.
54. Powell DW. Barrier function of epithelia function of epithelia. Am J Physiol. 1981;241:G275-88.